101565-92-8

Basic information

• Product Name: Adenosine, N-(3-thienylMethyl)-
• Synonyms: Adenosine, N-(3-thienylMethyl)-
• CAS NO: 101565-92-8
• Molecular Formula: C15H17N5O4S
• Molecular Weight: 363.39158
• EINECS: -0
• Mol File: 101565-92-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Adenosine, N-(3-thienylMethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Adenosine, N-(3-thienylMethyl)-(101565-92-8)
• EPA Substance Registry System: Adenosine, N-(3-thienylMethyl)-(101565-92-8)

Safety Data

• Hazardous Substances Data: 101565-92-8(Hazardous Substances Data)

Upstream product

• 42466-50-2 3-thiophenecarbaldoxime hydrochloride 
• 498-62-4 3-thiophene carboxaldehyde 
• 2004-06-0 6-Chloropurine riboside 
• 27757-86-4 (3-thienylmethyl)amine 

Relevant articles and documents

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N6-[(3-halothien-2-yl)methyl]adenosine, N6-[(4-halothien-2-yl)methyl]adenosine, and N6-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N6-[(2-bromothien-3-yl)methyl]adenosine, N6-[(4-bromothien-3-yl)methyl]adenosine, N6-[(5-bromothien-3-yl)methyl]adenosine N6-[(2-chlorothien-3-yl)methyl]adenosine, N6-[(4-chlorothien-3-yl)methyl]adenosine, and N6-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting ofN 6 -[(3-halothien-2-yl)methyl]adenosine,N 6 -[(4-halothien-2-yl)methyl]adenosine, andN 6 -[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting ofN 6 -[(2-bromothien-3-yl)methyl]adenosine,N 6 -[(4-bromothien-3-yl)methyl]adenosine,N 6 -[(5-bromothien-3-yl)methyl]adenosineN 6 -[(2-chlorothien-3-yl)methyl]adenosine,N 6 -[(4-chlorothien-3-yl)methyl]adenosine, andN 6 -[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N66-[(3-halothien-2-yl)methyl]adenosine, N66-[(4-halothien-2-yl)methyl]adenosine, and N66-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N66-[(2-bromothien-3-yl)methyl]adenosine, N66-[(4-bromothien-3-yl)methyl]adenosine, N66-[(5-bromothien-3-yl)methyl]adenosine N66-[(2-chlorothien-3-yl)methyl]adenosine, N66-[(4-chlorothien-3-yl)methyl]adenosine, and N66-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Dog Coronary Artery Adenosine Receptor: Structure of N6-Aryl Subregion

Previous structure-coronary vasoactivity correlations of the N6-alkyladenosine analogues of N6-adenosine, 1, support the hypothesis that the coronary artery A2 adenosine receptor contains an N6 region of specialized structure.The part of this receptor region that binds the 2-propyl moiety of 1 determines stereoselectivity and contributes to coronary vasoactivity.The present study uses 92 adenosine analogues containing an aryl group in the N6 substituent to test the hypothesis that the N6 receptor region contains and aryl subregionthat binds the phenyl moiety of 1 and thereby contributes to its coronary vasoactivity.N6-Aralkyladenosines are often more potent than their alkyl congeners.Two methylene residues seem to provide optimum separation of the aryl group from N6.Among adenosines with semirigid N6 substituents, N6-adenosine was uniquely active, evidence that when 1 occupies the receptor, the axis of the propyl C-1 to phenyl C-1 bond is nearly in the plane described by N6 and propyl C-1 and C-2.The torsion angle around this bond is unknown.Replacing the phenyl group of N6-2-phenethyladenosine with a thienyl or a 3-pyridyl group raises activity.The structure-activity relationships of the N6-(arylethyl)-, the N6-(arylmethyl)-, and the N6-phenyladenosines differ strinkingly from each other.Taken together, such results support the idea that the N6 region of the dog coronary artery A2 adenosine receptor includes an aryl subregion.